Cite

HARVARD Citation

    Kim, B. et al. (2022). Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma. Journal of gastroenterology and hepatology. 37 (3), pp. 428-439. [Online]. 
  
Back to record